Researchers Warn Against A Potential Backfiring Of Certain Cancer Therapies In Development
The cells of our body consume various nutrients from which they draw energy for their daily needs, with the help of inhaled oxygen. Glucose, for example, has a maximal energetic yield after complete combustion in mitochondria - genuine intracellular power plants. Even without oxygen, this nutrient may still provide some energy after being partially digested in the cell's cytoplasm. "This is the process - similar to fermentation - that is frequently used by tumor cells, allowing them to proliferate rapidly and free themselves, for the most part, of oxygen. They offset low energy output by consuming more glucose", notes Didier Picard, professor at the Department of cell biology of the Faculty of Science at UNIGE.
A shield for malignant cells
Some types of tumors are characterized by an excessive expression of TRAP1, a molecule present in mitochondria. This protein, which belongs to the "molecular chaperone" family, plays a role in protecting against cell auto-destruction and the damage done to its DNA in response to free radicals and other types of stress. "The antioxidant and cytoprotective properties of TRAP1, whose malignant cells use as a shield, have designated this protein as a target for antitumor treatments. Furthermore, TRAP1 inhibitors have demonstrated anticancerous activity in preclinical trials," explains Guillaume Mühlebach, first co-author of the article.
Alternate methods of energy production...
Tumor development occurs in several stages, with distinct metabolic needs. In collaboration with teams in the United States and Japan, researchers in Geneva have demonstrated that the expression of TRAP1 is inversely correlated with tumor stage in various types of human cancers. "In particular, we found that TRAP1 regulates a metabolic 'switch' at the level of glucose digestion. When this protein is overexpressed, as is often the case in primary tumors, the cells use fermentation to generate the resources for growth," explains Didier Picard.
...according to current needs
On the other hand, in a more advanced tumor stage, the expression of TRAP1 decreases and the cells mainly proceed to a complete combustion of nutrients in mitochondria. This metabolic pathway, with high energy output and high oxygen consumption, could provide them the energy necessary to form metastases. "The lack of TRAP1 indeed translates into a dramatic increase in cell motility and invasive power," says Evangelia Vartholomaiou, another member of the Geneva group.
The anticancerous strategies targeting this protein could therefore have adverse effects on tumors capable of promoting one metabolic pathway over another according to their needs. While simultaneously inhibiting cell proliferation, this type of treatment could actually stimulate progression into a metastatic state.
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
de Genève, Université. "Researchers Warn Against A Potential Backfiring Of Certain Cancer Therapies In Development." Medical News Today. MediLexicon, Intl., 3 Apr. 2013. Web.
25 Feb. 2017. <http://www.medicalnewstoday.com/releases/258480.php>
de Genève, U. (2013, April 3). "Researchers Warn Against A Potential Backfiring Of Certain Cancer Therapies In Development." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.